Some insiders emphasize the importance of doing rapid turnaround testing of asymptomatic people, while others contend lab tests ought to be the modality of choice.
The company said that its Access Interleukin-6 assay is designed to assist physicians in the identification of severe inflammatory response in COVID-19 patients.
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
